Akeso Printed Ivonescimab plus Ligufalimab as First-Line Therapy for PD-L1-Optimistic Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com
Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated HONG KONG, Sept.…
Citi lifts Akeso inventory goal with Purchase ranking on robust medical information By Investing.com
Citi has elevated its value goal for Akeso Inc (9926: HK) shares…
